United States: Court Dismisses Biosimilar Petitioner's IPR Appeal For Lack Of Standing

In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Co., the Federal Circuit dismissed Momenta's appeal from an adverse IPR decision for lack of standing after Momenta suspended its potentially infringing biosimilar development activity. Although Momenta had been pursuing such activity when appellate proceedings began, the court dismissed the appeal for mootness/lack of standing because Momenta had ceased its development program and "no concrete plans [were] afoot" implicating the patent claims challenged in the underlying IPR.1

Momenta's Procedural Evolution

In July 2015, Momenta petitioned the PTO for inter partes review of all claims in Bristol-Myers Squibb's U.S. Patent No. 8,476,239. The '239 Patent covers fluid formulations of CTLA4Ig, the active immunosuppressive agent in BMS's rheumatoid arthritis treatment ORENCIA®. Following IPR proceedings, the PTAB sustained patentability of all claims in the '239 Patent.2 Momenta appealed the Board's Final Written Decision to the Federal Circuit, under 35 U.S.C. § 319.3 Highlights from the appeal's procedural evolution are summarized below:

  • When Momenta petitioned for IPR in 2015, it was developing its ORENCIA® biosimilar in collaboration with Mylan N.V.
  • However, when Momenta appealed the PTAB's decision in 2017, its proposed biosimilar product had failed Phase 1 clinical trials. BMS moved to dismiss for lack of standing because Momenta had not filed a Biologics License Application at the FDA and had publicly stated that development would proceed regardless of the outcome on appeal.4
  • On September 19, 2017, Momenta responded that it had standing because (1) it had invested "millions of dollars" into developing a formulation that potentially infringed the '239 Patent, (2) was forced to adjust its business strategy, and (3) was injured-in-fact by the AIA estoppel provisions of § 315(e).5
  • On October 1, 2018, Momenta filed a letter with the court including a press release announcing that "[t]he Company has initiated discussions with its collaboration partner, Mylan, to exit its participation in the development of ... M834, a proposed biosimilar to ORENCIA® ...."6
  • On October 23, 2018, the court issued an Order to Show Cause why the appeal should not be dismissed as moot. Momenta responded, citing its joint responsibility with Mylan for substantial product development costs and its potential right to royalties from Mylan should the product be developed.7
  • On December 10, 2018, BMS filed a letter including documents that Momenta had filed four days earlier with the SEC, which stated:

We have elected to terminate our collaboration agreement with Mylan with respect to the development of ... M834, a proposed biosimilar to ORENCIA® .... On November 19, 2018, we delivered a formal notice of this partial termination to Mylan, as provided in the collaboration agreement.8

Momenta neither responded nor withdrew its appeal.

The Federal Circuit's Holding

The Federal Circuit dismissed the appeal, holding that Momenta lacked standing, despite pursuing infringing activity when the proceedings began.

[E]ven though Momenta may have been working in pursuit of potentially infringing activity, it is established that jurisdiction must exist throughout the judicial review, and an intervening abandonment of the controversy produces loss of jurisdiction.9

According to the court, "In essence, 'mootness is the doctrine of standing set in a time frame; that is, the requisite personal interest that must exist at the time of commencement of the litigation (standing) must continue throughout its existence (mootness).'"10 Given that Momenta had ceased the ORENCIA® biosimilar development program, the court concluded there was no potential for injury, "thereby mooting the inquiry."11

Momenta did not persuade the court that it had standing based on lost possible future royalties, should Mylan eventually develop an ORENCIA® biosimilar product.12 Instead, the court agreed with BMS that "possible future royalty ... is too speculative to support standing,"13 especially when such injury is based on "the unfettered choices made by independent actors not before the court."14

Without deciding the issue, the Federal Circuit also dismissed Momenta's argument that the AIA's estoppel provision independently supports Article III standing. (Under 35 U.S.C. § 315(e), IPR petitioners are estopped from later raising before the PTO, a U.S. district court, or the ITC any ground of invalidity that the petitioner "raised or reasonably could have raised" during the IPR.) As the court stated, "[E]stoppel of Momenta is irrelevant now that Momenta has 'exited' its development of the Orencia® product. Estoppel cannot constitute an injury-in-fact when Momenta 'is not engaged in any activity that would give rise to a possible infringement suit.'"15

Another Precedent in the Federal Circuit's Standing Jurisprudence

This case adds a new piece to the Federal Circuit's recent jurisprudence on Article III standing in IPR appeals. Judge Newman contrasted Momenta's circumstances to those of the petitioner in E.I. DuPont de Nemours & Co. v. Synvina C.V., where the Federal Circuit found DuPont satisfied "the irreducible constitutional minimum of standing."16 DuPont, a direct competitor of Synvina, built and operated a demonstration plant to produce furan dicarboxylic acid (FDCA), implicating patent claims challenged in the underlying IPR proceedings. According to the court, DuPont's endeavors evidenced "concrete plans" for present and "future activity that create a substantial risk of future infringement or likely cause the patentee to assert a claim of infringement."17 DuPont's ongoing, potentially infringing activity was sufficient to underwrite standing throughout the appeal.

Previously, we reported on JTEKT Corp. v. GKN Automotive Ltd., where the Federal Circuit held that the petitioner lacked standing to appeal an adverse IPR decision. According to the court in that case, the petitioner lacked a final product design that could support an infringement analysis for its drivetrain concept and therefore could not demonstrate "concrete plans for future activity" that posed substantial future infringement risk.18 Unlike JTEKT, Momenta satisfied the Article III standing requirements when it first appealed to the Federal Circuit, but it did not maintain standing throughout appellate proceedings like DuPont.

The takeaway here is that potentially infringing activity must persist throughout an appeal to support Article III standing and avoid dismissal for mootness. Petitioners who appeal adverse IPR decisions should be mindful that abandoning potentially infringing activity (or making public statements indicating such abandonment) may trigger dual risks: dismissal at the Federal Circuit, to go along with estoppel under the AIA.19


1 Momenta Pharm., Inc. v. Bristol-Myers Squibb Co., No. 2017-1694, 2019 WL 470177, at *4 (Fed. Cir. Feb. 7, 2019).

2 See Momenta Pharm., Inc. v. Bristol-Myers Squibb Co., IPR2015-01537, 2016 WL 7987985 (P.T.A.B. Dec. 22, 2016).

3 "A party dissatisfied with the final written decision of the Patent Trial and Appeal Board under section 318(a) may appeal the decision pursuant to sections 141 through 144. Any party to the inter partes review shall have the right to be a party to the appeal." 35 U.S.C. § 319; see also § 141(c).

4 Brief for Respondent at 3, Momenta, 2019 WL 470177 (Fed. Cir. filed Sept. 12, 2017).

5 Reply Brief for Appellant at 19, Momenta, 2019 WL 470177 (Fed. Cir. filed Sept. 19, 2017).

6 Momenta, 2019 WL 470177, at *1.

7 See id. at *2.

8 Id.

9 Id. at *4.

10 Id. at *5 (quoting Milwaukee Police Ass'n v. Bd. of Fire & Police Comm'rs, 708 F.3d 921, 929 (7th Cir. 2013)).

11 Id.

12 Id. at *4.

13 Id. at *2 (citing Clapper v. Amnesty Int'l USA, 568 U.S. 398, 402, 409 (2013) ("[W]e have repeatedly reiterated that 'threatened injury must be certainly impending to constitute injury in fact,' and that '[a]llegations of possible future injury' are not sufficient.").

14 Id. at *4 (quoting Clapper, 568 U.S. at 414 n.5).

15 Id. (quoting Consumer Watchdog v. Wis. Alumni Res. Found., 753 F.3d 1258, 1262 (Fed. Cir. 2014)).

16 904 F.3d 996, 1004 (Fed. Cir. 2018) (quoting Lujan v. Defenders of Wildlife, 504 U.S. 555, 560 (1992)).

17 Id. at 1005.

18 JTEKT Corp. v. GKN Auto. Ltd., 898 F.3d 1217, 1221 (Fed. Cir. 2018).

19 We note here that JTEKT has petitioned the United States Supreme Court for certiorari to review the Federal Circuit's decision. One question presented is whether the Federal Circuit can refuse to hear an appeal from an adverse final decision in an IPR when Congress has created the AIA estoppel provisions (i.e., whether the AIA estoppel provisions independently create injury-in-fact). See Petition for Writ of Certiorari, JTEKT Corp. v. GKN Auto. Ltd., No. 18-750 (Dec. 12, 2018). Stay tuned for further developments on this important issue.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions